Protalix BioTherapeutics (PLX) Depreciation & Amortization - Total (2024 - 2026)

Protalix BioTherapeutics' Depreciation & Amortization - Total history runs 3 years deep, the most recent figure standing at $404000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization - Total rose 16.76% year-over-year to $404000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 14.68% YoY), while the FY2025 annual figure was $1.5 million, up 12.35% from the prior year.
• Depreciation & Amortization - Total was $404000.0 for Q1 2026 at Protalix BioTherapeutics, up from $387000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $404000.0 in Q1 2026 to a low of $319000.0 in Q2 2024.
• Historically, Depreciation & Amortization - Total has averaged $356375.0 across 3 years, with a median of $353000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization - Total grew 12.85% in 2025, then grew 16.76% in 2026.
• A 3-year view of Depreciation & Amortization - Total shows it stood at $334000.0 in 2024, then advanced by 15.87% to $387000.0 in 2025, then grew by 4.39% to $404000.0 in 2026.
• The last three Depreciation & Amortization - Total figures came in at $404000.0 (Q1 2026), $387000.0 (Q4 2025), and $372000.0 (Q3 2025), per Business Quant data.